In the latest analyst update on Sage Therapeutics (SAGE, Financial), HC Wainwright & Co. has reiterated its neutral rating. Analyst Douglas Tsao has maintained his previous price target of $12.00 USD on SAGE shares. This update was released on June 17, 2025.
The current price target of $12.00 remains unchanged from the prior evaluation, reflecting a stable outlook as assessed by the firm. There has been no percentual change in the price target, and the neutral rating suggests a balanced perspective on the stock's potential future performance.
Investors and market observers keeping an eye on Sage Therapeutics (SAGE, Financial) should note this consistent standpoint by HC Wainwright & Co., as it indicates a steady position on the stock amidst varying market conditions.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 16 analysts, the average target price for Sage Therapeutics Inc (SAGE, Financial) is $8.52 with a high estimate of $12.00 and a low estimate of $5.00. The average target implies an downside of 5.95% from the current price of $9.06. More detailed estimate data can be found on the Sage Therapeutics Inc (SAGE) Forecast page.
Based on the consensus recommendation from 17 brokerage firms, Sage Therapeutics Inc's (SAGE, Financial) average brokerage recommendation is currently 2.9, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Sage Therapeutics Inc (SAGE, Financial) in one year is $182.36, suggesting a upside of 1912.8% from the current price of $9.06. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Sage Therapeutics Inc (SAGE) Summary page.
